Soleno therapeutics inc (SLNO)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Sep'14Mar'14Sep'13
Product revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

92

97

22

-

-

-

Government grant revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

155

-

-

-

-

-

Product revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2

447

-

247

-

-

-

-

-

Cost of product revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

51

461

-

56

22

18

-

-

-

Gross loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-49

-14

-

191

75

4

-

-

-

Operating expenses
Research and development

6,695

5,272

4,490

3,745

2,760

2,192

2,092

1,714

1,180

1,023

946

773

327

-890

708

658

1,772

-3,252

1,193

1,181

878

717

372

745

Sales and marketing

-

-

-

-

-

-

-

-

-

0

-1

0

27

-703

0

165

538

-

467

506

260

84

-

-

General and administrative

2,003

1,608

1,615

1,695

2,012

1,365

1,558

1,766

1,867

1,685

1,685

2,195

1,019

1,454

1,260

1,423

1,939

1,553

1,714

1,432

1,292

522

312

248

Change in fair value of contingent consideration

584

-128

28

183

206

-22

228

-67

428

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of contingent consideration

-

-

-

-

-

-

-

-

-

-

-

-

5

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

9,282

6,752

6,133

5,623

4,978

3,535

3,878

3,413

3,475

5,199

2,631

2,968

1,373

-138

1,968

2,246

4,249

-2,931

3,374

3,119

2,430

1,323

684

993

Operating loss

-9,282

-6,752

-6,133

-5,623

-4,978

-3,535

-3,878

-3,413

-3,475

-5,199

-2,631

-2,968

-1,373

201

-1,968

-2,295

-4,263

2,661

-3,183

-3,044

-2,426

-1,323

-684

-993

Other income (expense)
Cease-use income

-

-

-

-

-

-

0

3

3

1

5

0

-2

0

0

0

-94

0

0

0

0

-

-

-

Interest Income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

Interest expense, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

1

752

388

571

Change in fair value of warrants liabilities

-3,413

7,894

-7,116

4,267

1,919

-2,071

-1,543

3,255

-163

656

-131

91

69

-353

-200

56

-1,170

-660

-73

-4,925

6,174

-

-246

-

Loss from minority interest investment

-

0

-123

-165

-190

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest and other income (expense)

-

-

-

-

-

-

-

-

-

-

-

-3

601

-

-

-

-

-

-

-

-

-

-

-

Other expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-40

9

16

2

0

183

0

0

-

-

-

Inducement charge for Series C warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0

0

0

3,050

-

-

-

Interest income

11

21

29

47

57

29

26

30

19

167

3

-88

-672

393

191

-72

1,074

661

-110

4,925

-9,225

-318

-8

-26

Total other income (expense)

3,424

-7,873

7,022

-4,385

-2,052

3,928

1,569

-3,222

185

-

139

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss from continuing operations

-

-

889

-10,008

-

393

-2,309

-6,635

-3,290

-4,199

-2,492

-3,056

-2,045

-

-1,777

-2,367

-

-

-

-

-

-

-

-

Operating loss

-

-

-

-

-

-

-

-

-

-

-1,086

-

-

-

-973

-

-

-

-

-

-

-

-

-

Loss on sale of assets

-

-

-

-

-

-

-

-

-

-

-208

-

-

-

0

-

-

-

-

-

-

-

-

-

Loss from discontinued operations

-

-

-

-

-

-130

-427

-423

-514

-544

-1,294

-913

-842

-

-973

-1,146

-

-

-

-

-

-

-

-

Net loss

-5,858

-14,625

889

-10,008

-7,030

263

-2,736

-7,058

-3,804

-4,743

-3,786

-3,969

-2,887

-2,613

-2,750

-3,513

-3,189

-2,845

-3,293

1,881

-11,651

-2,393

-834

-1,590

Basic

-

-

0.03

-

-

-

-0.11

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Diluted

-

-

-0.19

-

-

-

-0.11

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Basic

-

-

-

-

-

-

-0.02

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Diluted

-

-

-

-

-

-

-0.02

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss per common share from continuing operations, basic and diluted

-

-

-

-0.31

-

-

-

-0.33

-0.17

-0.33

-0.26

-0.32

-0.40

-

-0.56

-0.15

-

-

-

-

-

-

-

-

Loss on extinguishment of convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

Net loss applicable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3,293

-

-

-

-

-

Operating (in usd per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.31

-

-

-

-

-

-

-

-

-

Loss on sale of assets (in usd per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.00

-

-

-

-

-

-

-

-

-

Loss per common share from discontinued operations, basic and diluted

-

-

-

-

-

-

-

-0.02

-0.02

0.00

-0.13

-0.10

-0.17

-

-0.31

-0.07

-

-

-

-

-

-

-

-

Net loss per common share, basic and diluted

-0.13

-

-

-0.31

-0.22

-

-

-0.35

-0.19

-0.33

-0.39

-0.42

-0.57

216.03

-0.87

-0.23

-220.00

-

-0.33

-

-1.67

-4.47

-1.56

-2.97

Weighted-average common shares outstanding used to calculate basic and diluted net loss per common share

44,679

-

-

31,776

31,756

-

-

20,345

19,530

11,633

9,670

9,516

5,090

-14,802,394

3,152

15,528

14,796,119

-

10,040

-

6,965

535

535

535

Basic

-

-

0.03

-

-

-

-0.13

-

-

-

-

-

-

-

-

-

-

-

-

0.25

-

-

-

-

Diluted

-

-

-0.19

-

-

-

-0.13

-

-

-

-

-

-

-

-

-

-

-

-

0.25

-

-

-

-

Basic

-

-

31,793

-

-

-

21,432

-

-

-

-

-

-

-

-

-

-

-

-

7,517

-

-

-

-

Diluted

-

-

32,443

-

-

-

21,432

-

-

-

-

-

-

-

-

-

-

-

-

7,630

-

-

-

-